Christopher Pearce - Chief Executive
Christopher Pearce has built the Group since inception and has been responsible for the formulation and implementation of strategy, collaborative and licensing agreements, and intellectual property. He was co-founder and Executive Chairman of Fitness First plc, the international fitness chain.
James Malthouse - Finance Director
James Malthouse joined the Group in 1993 and is a Chartered Accountant with banking and corporate finance experience. He was Chairman and Finance Director of Unigroup plc and Finance Director of Harcourt Group plc.
Dr. Ian Pike – Chief Operating Officer
Ian Pike has over 20 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Wellcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialisation of a wide portfolio of technologies related to the biomedical sector. Most recently, Ian worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA.
R. Steven Harris – Chairman (i) (ii)
Steve Harris is a Fellow of the Royal Pharmaceutical Society. Until June 1995 he was Director of Development and Licensing at Medeva plc. He has worked in the pharmaceutical industry for 45 years including with ICI, Merck Sharp & Dohme, Eli Lilly, Boots, Reckitt and Colman, and Gensia. He is non-executive Director of Advanced Medical Solutions plc and Phynova plc and is non-executive Chairman of Cyprotex plc, Aquapharm Biodiscovery Ltd and Ocelus Ltd.
Professor William Dawson (i) (ii)
Professor William Dawson retired from Eli Lilly and Company in August 1996 after 27 years' service, 14 as Research Director in the UK and latterly as Director of Technology Acquisition, Europe. He is a Director of Bionet Ltd, Pharmovation Ltd, Novolytics Ltd, Antitope Ltd and a Fellow of the Royal Pharmaceutical Society and of the Royal Society of Chemistry.
Dr. Anthony Walker (i) (ii)
Dr. Anthony Walker has considerable commercial and scientific expertise in the life sciences and biotechnology industries with 12 years as CEO of Onyvax, a cancer vaccines company he co-founded in 1997, and currently as a partner of Alacrita LLP. He spent 10 years as a management consultant specialising in the pharmaceutical and biotechnology industries initially at Arthur D. Little where he launched the UK Pharmaceutical Practice and subsequently at Wilkerson Group.
(i) Member of Audit Committee
(ii) Member of Remuneration Committee
